Theravance Biopharma to Present at the 40th Annual J.P. Morgan Healthcare Conference
Theravance Biopharma (NASDAQ: TBPH) will present at the J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Theravance Biopharma (NASDAQ: TBPH) will present at the J.P. Morgan 40th Annual Healthcare Conference on January 13, 2022, at 12:00 PM ET. The webcast can be accessed on the company's website under the Investors section, and a replay will be available for 30 days. Theravance focuses on respiratory medicines, boasting FDA-approved YUPELRI® for COPD. The company is committed to developing transformative therapies to improve respiratory health.
Details
News Market Reaction – TBPH
The recorded move for TBPH in the trading session of this news was -3.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Jan. 5, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will present as follows:
- J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, at 12:00 pm ET (9:00 am PT/5:00 pm GMT)
Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness.
In pursuit of its purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference. These efforts have led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the US and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-301454139.html
SOURCE Theravance Biopharma, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.